Drug Profile
Research programme: neurological disorders therapeutics - Athira Pharma
Latest Information Update: 18 Oct 2022
Price :
$50
*
At a glance
- Originator M3 Biotechnology
- Developer Athira Pharma
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Amyotrophic lateral sclerosis; Neuropathic pain
- No development reported Neurodegenerative disorders
Most Recent Events
- 04 Oct 2022 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO)(Athira pipeline, October 2022)
- 04 Oct 2022 Preclinical trials in Neuropathic pain in USA (PO)(Athira pipeline, October 2022)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in USA